the Role of Technology in Elderly Patients (SILVER)
Fighting Against Social Isolation in Times of Pandemic Corona Virus-19: the Role of Technology in Elderly Patients: The SILVER Study
Starting from December 2019, the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) disease spread rapidly from China into the world, with about two Mio cases confirmed around the world. In Switzerland, more than 26'000 cases have been confirmed so far, and health authorities declared in March the needs for social isolation and have banned visits to hospitalized patients and to nursing home residents. Loneliness and isolation is a significant concern for the elderly patients as well as for their families that may significantly affect physical and mental health in both.
SILVER aims to evaluate the role of programmed video calls with families:
- on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-COV-2 pandemic.
- in relieving the familiar caregiver anxiety and fear of death of others
- in relieving the professional caregiver anxiety.
SILVER is an international study involving both acute, rehabilitation geriatric units and nursing homes; we will enroll all the patients present in the participating centers. Patients will be allowed to chose between video and phone calls, the following dimensions will be evaluated:
- Delirium risk: using the Confusion Assessment Method (CAM)
- Mood: using the 5-item Geriatric Depression Scale (GDS)
- Anxiety: using the Clinical Anxiety Scale (GAS).
- Fear of death (self and others): using the Collett-Lester scale. In parallel, health professionals and family caregivers will be evaluated for anxiety at baseline and every week after intervention set-up by the Clinical Anxiety Scale (CAS). Family caregivers will also be evaluated with the fear of death scale (sub-scale fear of death of others).
Finally, to evaluate the appreciation for video call communication in patients and caregivers we will use a Likert scale.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Aims.
- To evaluate the role of video calls with families on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-CoV-2 pandemic.
- To evaluate the role of video calls in relieving family caregivers' anxiety and fear of death of their loved one.
- To evaluate the role of video calls in relieving health professionals' anxiety.
Methods. In order to reduce social isolation from their relatives and friends patients will be helped in joining them through video-calls thanks to the use of dedicated tablets and to the assistance provided by nurses, assistant-nurses, occupational therapists or neuropsychologists.
Population selection. All the patients in the participating centers fulfilling inclusion/exclusion criteria will be enrolled in SILVER.
Patients will be asked to chose between video and phone call, phone call will be allowed without any restriction to both video and usual care groups.
standardization of video calls: Two video-calls of maximum 15' will be administered every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time, the use of others app will be evaluated upon family's request.
Data collection for primary and secondary outcomes. Patients will be evaluated at baseline and every week with standardized scales to assess their mood, anxiety and delirium symptoms.
At baseline and at the end of the intervention we will evaluate the overall appreciation of the video call by the patients, their family caregiver, and the health professionals using a Likert scale and Anxiety: using the Geriatric Anxiety Scale (GAS).
In order to clarify the role of social connection through video calls on the patients' health, we will evaluate at baseline and after one week :
- Mood: using the 5-items Geriatric Depression Scale (GDS-5)
- Fear of death (self and others): using the Collett-Lester scale
- Delirium risk: using the Confusion Assessment Method (CAM) will be evaluated every day and will be analyzed ad day of delirium weekly.
In addition, the effect of video calls in professionals and in family caregivers will be evaluated as follows:
family and professional caregivers will be evaluated for anxiety at baseline and the end of intervention set-up by the Clinical anxiety (CAS). Familiar care-givers will also be evaluated with the fear of death scale (sub-scale fear of death of others) at the baseline and after one week.
Collection of other data.
In order to correct the statistical analyses for possible confounding variables the following data will be collected:
Age, gender, years of school, duration of hospitalization , type of hospital discharge, Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, Cumulative Illness Rating Scale (CIRS) index, Activity of Daily Living (ADL), Instrumental Activities of Daily Living (IADL).
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Lausanne, Suiza, 1012
- Patrizia D'amelio
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- patients of 65 years and older hospitalized in the participating unit during the absence of visits due to the SARS-CoV2 pandemic.
- Patients and families willing to participate.
Exclusion Criteria:
- patients or families who refuse to participate.
- Clinical Dementia Rating (CDR) equal or higher than two.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
phone calls
patients choosing phone calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Otros nombres:
|
|
video call
patients choosing video calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
4-point likert scale (LKRT)
Periodo de tiempo: 0-7 days
|
appreciation of video calls by patients and families rage 0-4, 4 represent the better outcome
|
0-7 days
|
|
Geriatric anxiety scale (GAS-10)
Periodo de tiempo: 0-7 days
|
measure of anxiety, The GAS-10 form, contains a total of 10 items, the answers are yes or no and the possible scores range from 0 to 10, with a cut-off point for anxiety at 6.
The higher the score, the greater the anxiety.
|
0-7 days
|
|
Collett Lester Fear of Death scale (CL-FOD) for self and others
Periodo de tiempo: 0-7 days
|
fear of death scale of patients, The CL-FODS contains 28 items, with seven items on each of the four subscales: Fear of Death of Self, Dying of Self, Death of Others, and Dying of Others.
It is answered on a 5-point Likert format anchored as follows: 1 (not) and 5 (very).
The total score in each subscale could range from 7 to 35, with higher scores denoting higher anxiety from death or dying.
|
0-7 days
|
|
geriatric depression scale (GDS-5)
Periodo de tiempo: 0-7 days
|
mood evaluation for patients.
the GDS-5 contains 5 items, the total score range from 0 to 5, the clinical cut-off for suspicion of depression is 2
|
0-7 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Collett Lester Fear of Death scale (CL-FOD) for others
Periodo de tiempo: 0-7 days
|
fear of death scale of others for family
|
0-7 days
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 2020-01125
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .